@Article{,
AUTHOR = {Aalya Hamouda, Ahmed Ibrahim, Nicholas Corsi, Giampaolo Siena,Dean S. Elterman, Bilal Chughtai, Naeem Bhojani, Francesco Sessa, Anna Rivetti, Silvia Secco, Kevin C. Zorn},
TITLE = {Use of the Schelin Catheter for transurethral intraprostatic anesthesia prior to Rez ūm treatment},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {31},
YEAR = {2024},
NUMBER = {1},
PAGES = {11802--11808},
URL = {http://www.techscience.com/CJU/v31n1/59611},
ISSN = {1488-5581},
ABSTRACT = {Minimally invasive surgery techniques (MIST) have
become newly adopted in urological care. Given this,
new analgesic techniques are important in optimizing
patient outcomes and resource management. Rez ūm
treatment (RT) for BPH has emerged as a new MIST with
excellent patient outcomes, including improving quality
of life (QoL) and International Prostate Symptom Scores
(IPSSs), while also preserving sexual function. Currently,
the standard analgesic approach for RT involves a peri
prostatic nerve block (PNB) using a transrectal ultrasound
(TRUS) or systemic sedation anesthesia. The TRUS approach is invasive, uncomfortable, and holds a risk
of infection. Additionally, alternative methods such as,
inhaled methoxyflurane (Penthrox), nitric oxide, general
anesthesia, as well as intravenous (IV) sedation pose safety
risks or mandate the presence of an anesthesiology team.
Transurethral intraprostatic anesthesia (TUIA) using
the Schelin Catheter (ProstaLund, Lund, Sweden) (SC)
provides a new, non-invasive, and efficient technique for
out-patient, office based Rez ūm procedures. Through local
administration of an analgesic around the prostate base,
the SC has been shown to reduce pain, procedure times,
and bleeding during MISTs. Herein, we evaluated the
analgesic efficacy of TUIA via the SC in a cohort of 10
patients undergoing in-patient RT for BPH.},
DOI = {}
}